Is OSR Holdings, Inc. (OSRH) Halal?

NASDAQ Healthcare United States $12M
✓ HALAL
Confidence: 95/100
OSR Holdings, Inc. (OSRH) is Halal under 3 of 5 Shariah screening standards, including AAOIFI Standard 21. With a debt ratio of just 19.4% against the AAOIFI threshold of 30%, OSR Holdings, Inc. comfortably passes the key financial ratio tests. The company operates in the Healthcare sector (Biotechnology), which is not a prohibited industry under Islamic finance principles.

Shariah Screening — 5 Standards

Based on financial data from December 2024

Standard Debt Ratio Cash Ratio Receivables Income Status
AAOIFI 19.4%
/ 30%
0.5%
/ 30%
2.3%
/ 30%
N/A ✓ HALAL
DJIM 19.4%
/ 33%
0.5%
/ 33%
2.3%
/ 33%
N/A ✓ HALAL
MSCI 111.3%
/ 33%
2.9%
/ 33%
13.0%
/ 33%
N/A ✗ NOT HALAL
S&P 19.4%
/ 33%
0.5%
/ 33%
2.3%
/ 33%
N/A ✓ HALAL
FTSE 111.3%
/ 33%
2.9%
/ 33%
13.0%
/ 50%
N/A ✗ NOT HALAL

Financial Highlights

EPS
$-0.28
P/B Ratio
0.1
EV/EBITDA
18.9
EV: $66M
Revenue
$0
Growth: -23.7%
Beta
1.5
High volatility
Current Ratio
0.2

Profitability

Gross Margin 0.0%
Operating Margin -605.9%
Net Margin 0.0%
Return on Equity (ROE) -8.9%
Return on Assets (ROA) -1.8%

Cash Flow & Balance Sheet

Operating Cash Flow-$2M
Free Cash Flow-$2M
Total Debt$3M
Debt-to-Equity3.3
Current Ratio0.2
Total Assets$2M

Price & Trading

Last Close$0.44
50-Day MA$0.52
200-Day MA$0.71
Avg Volume1.4M
Beta1.5
52-Week Range
$0.38
$3.30

About OSR Holdings, Inc. (OSRH)

CEO
Mr. Kuk Hyoun Hwang
Employees
19
Sector
Healthcare
Industry
Biotechnology
Country
United States
Exchange
NASDAQ
Market Cap
$12M
Currency
USD

OSR Holdings, Inc., a healthcare holding company, develops a portfolio of therapies and healthcare solutions in the United States, Switzerland, and South Korea. The company develops immunotherapy products, including VXM01, an immuno-oncology candidate for glioblastoma that is in phase 2 clinical trial, as well as preclinical stage products, such as VXM04 to treat mesothelin; VXM06 for the treatment of Wilms Tumor Protein (WT1); VXM08 for Carcinoembryonic antigen (CEA); and VXM10 for PD-L1. It is also developing design-augmented (DA) biologics comprising DRT-102, a clinical-stage asset for spinal fusion; and DRT-101, a pre-clinical stage asset for osteoarthritis. In addition, the company distributes neurovascular intervention medical device and systems. OSR Holdings, Inc. is based in Bellevue, Washington.

Related Halal Stocks in Healthcare

Frequently Asked Questions

Is OSR Holdings, Inc. (OSRH) halal to invest in?

Based on our screening using AAOIFI Standard 21 (the strictest methodology), OSR Holdings, Inc. is Halal. The company passes all financial ratio thresholds for debt, cash, receivables, and impermissible income. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.

What is OSR Holdings, Inc.'s debt ratio?

OSR Holdings, Inc.'s debt ratio is 19.4% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 111.3%.

What are OSR Holdings, Inc.'s key financial metrics?

OSR Holdings, Inc. has a market capitalization of $12M. Return on equity stands at -8.9%.

How often is the screening data updated?

Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.

Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.